A look at Immunome Inc’s (IMNM) recent performance gives investors their first glimpse of hope.

On Tuesday, Immunome Inc (NASDAQ: IMNM) opened lower -4.52% from the last session, before settling in for the closing price of $10.40. Price fluctuations for IMNM have ranged from $8.97 to $30.96 over the past 52 weeks.

Company’s average yearly earnings per share was noted 17.82% at the time writing. With a float of $69.65 million, this company’s outstanding shares have now reached $84.67 million.

The firm has a total of 55 workers. Let’s measure their productivity. In terms of profitability, gross margin is 88.22%, operating margin of -3134.4%, and the pretax margin is -3014.59%.

Immunome Inc (IMNM) Insider Activity

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Immunome Inc is 17.74%, while institutional ownership is 63.10%. The most recent insider transaction that took place on Jan 31 ’25, was worth 1,162,500. In this transaction President and CEO of this company bought 150,000 shares at a rate of $7.75, taking the stock ownership to the 669,636 shares. Before that another transaction happened on Nov 21 ’24, when Company’s President and CEO bought 66,057 for $9.54, making the entire transaction worth $630,263. This insider now owns 485,693 shares in total.

Immunome Inc (IMNM) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 17.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.01% during the next five years compared to -48.48% drop over the previous five years of trading.

Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators

Check out the current performance indicators for Immunome Inc (IMNM). In the past quarter, the stock posted a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 83.00.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.12, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -3.09 in one year’s time.

Technical Analysis of Immunome Inc (IMNM)

Analysing the last 5-days average volume posted by the [Immunome Inc, IMNM], we can find that recorded value of 0.88 million was lower than the volume posted last year of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 20.70%. Additionally, its Average True Range was 0.84.

During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 15.41%, which indicates a significant decrease from 25.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.34% in the past 14 days, which was higher than the 73.73% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $11.06, while its 200-day Moving Average is $12.98. Now, the first resistance to watch is $10.46. This is followed by the second major resistance level at $10.99. The third major resistance level sits at $11.29. If the price goes on to break the first support level at $9.62, it is likely to go to the next support level at $9.32. Should the price break the second support level, the third support level stands at $8.79.

Immunome Inc (NASDAQ: IMNM) Key Stats

There are currently 79,777K shares outstanding in the company with a market cap of 840.82 million. Presently, the company’s annual sales total 14,020 K according to its annual income of -106,810 K. Last quarter, the company’s sales amounted to 2,910 K and its income totaled -47,100 K.